ARCHIVES

DCT Board Okays Recompetition of Drug Discovery Groups

This article is from The Cancer Letter archive.

Vol. 19 No. 41 | October 22, 1993

Download PDF Visit The Full Archive

Related Articles

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Accelerated Approval Will No Longer Block Competitors, FDA Commissioner Says

June 6, 2003

Chabner : Opportunity To Set Own Agenda Reason For Leaving

October 28, 1994

NCI Cooperative Groups Recognized By ASCO For 50+ Years Of Clinical Trials.

June 1, 2007

NCAB Approves Plan for National Black Leadership Initiative

October 16, 1987

Kennedy, Waxman Disagree On Authorization Issue; Legislation For NIH, NCI This Congress Threatened

September 26, 1980